Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 6.72 USD -6.93% Market Closed
Market Cap: 174.7m USD

Wall Street
Price Targets

RNAC Price Targets Summary
Cartesian Therapeutics Inc

Wall Street analysts forecast RNAC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNAC is 35.99 USD with a low forecast of 16.16 USD and a high forecast of 46.2 USD.

Lowest
Price Target
16.16 USD
140% Upside
Average
Price Target
35.99 USD
436% Upside
Highest
Price Target
46.2 USD
588% Upside
Cartesian Therapeutics Inc Competitors:
Price Targets
251120
Bio-FD&C Co Ltd
19% Upside
MOLN
Molecular Partners AG
170% Upside
MDGL
Madrigal Pharmaceuticals Inc
1% Upside
1530
3SBio Inc
47% Upside
GLTO
Galecto Inc
27% Upside
206650
EuBiologics Co Ltd
61% Upside
301207
Hualan Biological Bacterin Inc
3% Upside
005690
Pharmicell Co Ltd
11% Upside

Revenue
Forecast

Revenue Estimate
Cartesian Therapeutics Inc

For the last 9 years the compound annual growth rate for Cartesian Therapeutics Inc's revenue is 23%. The projected CAGR for the next 4 years is -11%.

23%
Past Growth
-11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Cartesian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
6%
Average Beat

Net Income
Forecast

Net Income Estimate
Cartesian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RNAC's stock price target?
Price Target
35.99 USD

According to Wall Street analysts, the average 1-year price target for RNAC is 35.99 USD with a low forecast of 16.16 USD and a high forecast of 46.2 USD.

What is Cartesian Therapeutics Inc's Revenue forecast?
Projected CAGR
-11%

For the last 9 years the compound annual growth rate for Cartesian Therapeutics Inc's revenue is 23%. The projected CAGR for the next 4 years is -11%.

Back to Top